

1 **New perspectives on bioactivity of olive oil – evidence from**
2 **animal models, human interventions and the use of urinary**
3 **proteomic biomarkers**

4 **By S. Silva^{1,2,3}, E. Combet⁴, M.E. Figueira^{3,5}, T. Koeck⁶, W. Mullen⁷ and M.R. Bronze^{1,2,3,5},**
5 *¹iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras,*
6 *Portugal ²ITQB, Instituto de Tecnologia Química e Biológica António Xavier, Universidade*
7 *Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal ³Pharmacy Faculty, University of*
8 *Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal, ⁴Human Nutrition, School of*
9 *Medicine, University of Glasgow, Glasgow G31 2ER, UK ⁴iMED.Ulisboa, Research Institute for*
10 *Medicines, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal ⁶Mosaiques diagnostics GmbH,*
11 *Mellendorfer Strabe 7-9, 30625, Hannover, Germany, and ⁷Institute of Cardiovascular and*
12 *Medical Sciences, University of Glasgow, Glasgow G12 8QQ, UK*

13
14

**This is a post peer review manuscript of the full paper
published in *Proceedings of the Nutrition* 08/2015; 74(3):268-
281. DOI:10.1017/S0029665115002323**

15
16

17 **Corresponding author:**

18 M. R. Bronze, Pharmacy Faculty, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa,
19 Portugal; telephone number (+351) 21 794 64 00 Ext. 14329; Fax number (+351) 217946470
20 email mrbronze@ff.ulisboa.pt.

21

22 **Short title: New perspectives on bioactivity of olive oil**

23

24 **Keywords: olive oil, phenolics, coronary artery disease, inflammation, proteomic**
25 **biomarkers**

26

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

Abstract

Olive oil (OO) is the primary source of fat in the Mediterranean diet and has been associated with longevity and a lower incidence of chronic diseases, particularly coronary heart disease. Cardioprotective effects of OO consumption have been widely related with improved lipoprotein profile, endothelial function and inflammation, linked to health claims of oleic acid and phenolic content of OO. With cardiovascular disease being a leading cause of death worldwide, a review of the potential mechanisms underpinning the impact of OO in the prevention of disease is warranted. The current body of evidence relies on mechanistic studies involving animal and cell-based models, epidemiological studies of OO intake and risk factor, small and large scale human interventions, and the emerging use of novel biomarker techniques associated with disease risk. While model systems are important for mechanistic research nutrition, methodologies and experimental designs with strong translational value are still lacking. This review critically appraises the available evidence to date, with particular focus on emerging novel biomarkers for disease risk assessment. New perspectives on OO research are outlined, especially those with scope to clarify key mechanisms by which OO consumption exerts health benefits. The use of urinary proteomic biomarkers, as highly specific disease biomarkers, is highlighted towards a higher translational approach involving olive oil in nutritional recommendations.

59

60 **1. Relevance of the Mediterranean diet and olive oil to health**

61 The olive tree, *Olea europaea* L., is one of the oldest agricultural tree crops and provides
62 diversified products for human consumption such as table olives and olive oil (OO)⁽¹⁾. The
63 analytical parameters to ascertain OO quality and classify OOs are defined by European Union
64 (EU) regulations⁽²⁾. Oils obtained only by mechanical extraction are virgin olive oils (VOOs) and
65 further quality assessment can lead to a classification as extra virgin olive oil (EVOO)⁽³⁾.

66 OO is the primary source of fat in the Mediterranean diet and has been associated with longevity
67 and a lower incidence of chronic diseases, particularly coronary heart disease (CHD)⁽⁴⁻⁷⁾. OO
68 consumption is also associated with decreased rates of cancer, diabetes and neurodegenerative
69 diseases⁽⁸⁾ as well as body weight reduction and obesity prevention^(9, 10). The epidemiological
70 evidence underpinning the relevance of the Mediterranean diet to health is strong with over
71 seventeen studies including 2300 volunteers confirming that a Mediterranean diet decreases
72 inflammation and improves endothelial function⁽¹¹⁾, and a meta-analysis of thirty-two cohort
73 studies (> 800,000 subjects) indicating that there is an inverse correlation between OO intake and
74 coronary heart disease⁽¹²⁾.

75

76 **Olive oil bioactive components**

77 The major components of OO are glycerols (saponifiable fraction) which represent more than
78 98% of of the total oil weight and are mainly triglyceride esters of oleic acid (55 to 83%),
79 palmitic acid (7.5 to 20%), linoleic acid (3.5 to 21%) and other fatty acids such as stearic acid
80 (0.5 to 5%)⁽¹³⁾. Minor components (the unsaponifiable fraction) include aliphatic and triterpenic
81 alcohols, sterols, hydrocarbons as squalene, volatile compounds, tocopherols, carotenes,
82 chlorophyll and phenolic compounds⁽¹³⁻¹⁵⁾.

83 Special attention has been given to the phenolic compounds only found in VOO and EVOO. The
84 agronomic and technological aspects of OO production have an impact on the concentration of
85 phenolic compounds, as does the pedoclimatic conditions and agronomic techniques
86 (e.g.: irrigation)^(4, 14). The main classes of phenolic compounds present in VOO are phenolic
87 acids, phenolic alcohols (hydroxytyrosol and tyrosol), flavonoids, lignans and secoiridoids,

88 **Table 1.**

89 Oleuropein and ligstroside, the most significant secoiridoids in *Olea europaea* L., are esters of
90 elenolic acid glucoside with hydroxytyrosol and tyrosol, respectively. During the mechanical

91 extraction of the oil, fruit endogenous β -glucosidases^(14, 16) are released leading to the secoiridoid
92 aglycones formation, accounting for more than 50% of the phenolic content of the oil^(17, 18). The
93 most abundant secoiridoids of VOO are the oleuropein and ligstroside aglycons and dialdehydic
94 forms of deacetoxy of oleuropein and ligstroside aglycons⁽¹⁴⁾ also named oleacein and
95 oleocanthal, respectively⁽¹⁹⁾.

96

97 **Phenolic compounds bioavailability and bioactivity**

98 Once OO has been ingested, it produces a micellar solution composed of a lipid and an aqueous
99 phase. Chemical hydrolysis of secoiridoids can take place in the acidic medium of the
100 stomach⁽²⁰⁾ or in alkaline conditions in the small intestine^(21, 22) leading to an increase of free
101 phenolic alcohols released into the aqueous phase. As a result OO phenolic compounds are
102 further absorbed in the small intestine⁽²³⁾. Measuring the bioavailability of these compounds in
103 plasma and urine reveals that OO phenolics undergo a conjugation process of methylation,
104 glucuronidation and sulfation indicating that there is phase 2 metabolism involved during the
105 absorption of these compounds⁽²⁴⁻²⁷⁾. The between-subjects variability in human absorption and
106 metabolism of OO phenolics may explain differences in proportion of methyl, glucuronide and
107 sulfate conjugates reported⁽²⁸⁻³⁰⁾.

108

109 Bioavailability of OO phenolic compounds differs according to the intake matrix. OO as the
110 intake vehicle promotes absorption of hydroxytyrosol: the corresponding bioavailability of
111 hydroxytyrosol in rats for aqueous and OO solutions were reported as 75 and 99%⁽³¹⁾,
112 respectively. When a supplement containing hydroxytyrosol as a single oral dose (2.5 mg/kg)
113 was fed to humans, the bioavailability was below 10%⁽³²⁾, while previous studies showed higher
114 bioavailability for hydroxytyrosol supplementation in lipid vehicles⁽³³⁾. The addition of
115 hydroxytyrosol to low fat yogurt and administered to humans was also associated with a lower
116 excretion of hydroxytyrosol when compared with OO⁽³³⁾. As OO phenolic compounds are mainly
117 absorbed in the small intestine⁽²³⁾ the increase of hydroxytyrosol bioavailability, in OO, might be
118 related to the rate of gastric emptying⁽³²⁾ and slow release of hydroxytyrosol from the oil
119 matrix^(26, 32). The presence of other antioxidants in OO might prevent breakdown of
120 hydroxytyrosol before absorption in the gastrointestinal tract⁽³¹⁾.

121

122 Secoiridoids that are not absorbed in the small intestine are degraded by the colonic microbiota
123 with oleuropein producing hydroxytyrosol as the major product⁽²⁰⁾. *In vitro* colonic metabolism
124 was evaluated on tyrosol, hydroxytyrosol, hydroxytyrosol acetate and oleuropein showing an
125 increase in phenolic acids, stability of hydroxytyrosol and tyrosol and degradation of
126 hydroxytyrosol acetate and oleuropein mainly to hydroxytyrosol⁽³⁴⁾. In order to evaluate OO
127 phenolic metabolites produced from colonic fermentation, faecal samples were analysed before
128 and after mid-term consumption of phenol-rich OO⁽³⁴⁾. A significant increase in hydroxytyrosol
129 concentration ($p < 0.05$) was observed after phenol-rich OO intake. Although absorption of OO
130 phenolic compounds mainly occur in the small intestine a small proportion of hydroxytyrosol
131 and its derivatives still pass into the large intestine⁽²³⁾. This highlights the need to study the
132 impact of OO phenolics in the colon, either with gut microbiota interaction or local activity due
133 to its antioxidant and anti-inflammatory properties.

134
135 When assessing the chemical and *in vitro* biological antioxidant activities of these compounds, it
136 is the glucuronides conjugates of hydroxytyrosol and tyrosol that must be assessed. These were
137 tested in the range 0.01–10 μM against the radical 1,1-diphenyl-2-picrylhydrazyl (DPPH). None
138 of the glucuronides displayed significant antioxidant activities at the concentrations tested,
139 whereas the parent aglycones did display antioxidant activity at these concentrations⁽³⁵⁾. This
140 conflicts with the results of others⁽³⁶⁾ with differences attributed to the fact that in one study
141 reference standard material⁽³⁵⁾ was used and in the other the glucuronide conjugates were
142 extracted from urine samples⁽³⁶⁾, and likely contained impurities that had antioxidant activity.
143 Hydroxytyrosol metabolites might act as "sinks" of hydroxytyrosol that could be locally released
144 in the cells after enzymatic hydrolysis⁽³⁷⁾, thereby explaining the proposed hydroxytyrosol
145 biological effects observed *in vivo*. Moreover, *in situ* deconjugation of hydroxytyrosol
146 metabolites (into their free form) in red blood cells was observed in rats after oral administration
147 of an OO phenolic extract obtained from olive cake (1.5 g/kg body weight, equivalent to 34.4 mg
148 of hydroxytyrosol and derivatives), highlighting a potential protective mechanism against cell
149 oxidative damage⁽³⁸⁾.

150
151 Although there are a number of biological effects for OO phenolic compounds, most cannot be
152 achieved via normal dietary exposure to OO. This has led to development of enriched products
153 with natural OO phenolic compounds. OO by-products such as olive mill wastewater⁽³⁹⁾ and

154 olive pomace^(40,41) are potential sources of natural bioactives which could be used to supplement
155 OO. The development of new OO products such as pomace OO or refined olive oil (ROO)
156 enriched in natural bioactives opens new perspectives in the field.

157

158 **2. Olive oil and inflammation**

159 Inflammation involves a complex cascade of events partly related with the production of an
160 excess of free radicals due to internal or environmental stress⁽⁴²⁾. The inflammation process
161 triggers signaling molecules such as nuclear factor-kappa-B (NF- κ B), which up-regulates the
162 production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF- α)⁽⁴³⁾ inducible
163 NO synthase (iNOS), cyclooxygenase-2 (COX-2), and interleukin-1beta (IL-1 β)⁽⁴²⁾.

164 A number of phenolic compounds present in OO have anti-inflammatory properties, including
165 oleocanthal, a secoiridoid (dose-dependent inhibition of COX-1 and COX-2 activities, similar to
166 the anti-inflammatory drug ibuprofen⁽⁴⁴⁾). However, to achieve comparable effect to the
167 recommended daily dose of ibuprofen, 500 g of EVOO would need to be consumed^(45,46) making
168 the dose/effect relationship outwith any (acute) inflammatory benefits due to typical OO
169 consumption.

170

171 **Chronic inflammation**

172 Rheumatoid arthritis (RA) is a major inflammatory, autoimmune, disease characterized by
173 chronic joint inflammation^(47,48). Hydroxytyrosol has been studied for its anti-inflammatory
174 effects in a RA animal model. We reported that it provided beneficial effects in the evolution of
175 the disease⁽⁴⁹⁾, with 0.5 and 5 mg/kg doses in rats, after gavage administration, using ROO as
176 vehicle (human-equivalent of 4.9 and 49 mg/day, respectively, for a 60 kg adult), **Figure 1**.
177 Significant effects, on paw edema reduction, were observed for a human-equivalent dose of
178 49 mg/day, a dose 10 times higher than the approved European Food Safety Authority (EFSA)
179 dose for phenolic compounds in relation to protection of lipid oxidation⁽⁵⁰⁾. The same
180 hydroxytyrosol dose was effective on colitis, another chronic inflammatory disease⁽⁵¹⁾. This dose
181 would only be achievable through nutraceutical supplementation of OO with hydroxytyrosol, and
182 the use of this functional food on a daily basis.

183 To further evaluate the anti-inflammatory mechanisms involved with hydroxytyrosol, we studied
184 COX-2 and iNOS expression⁽⁴⁹⁾. The treatment at 5 mg/kg dose significantly decreased
185 histological damage, COX-2 and iNOS expression ($p < 0.001$ vs. positive control), markedly

186 reduced the degree of bone resorption, soft tissue swelling and osteophyte formation, improving
187 articular function in treated animals. Moreover at the same dose there was a significant decrease
188 ($p < 0.005$ vs. positive control and ROO) in TNF- α serum levels. These results are in line with
189 others that reported benefits on RA, in animal models, after oral administration of an EVOO
190 extract⁽⁵²⁾, intraperitoneal administration of oleuropein aglycone⁽⁵³⁾ or polyphenol supplemented
191 VOOs diets⁽⁵⁴⁾. The reports highlight effects on RA of OO phenolic compounds either
192 administered as isolated compounds or as an extract. However, doses comparison between
193 animal studies have to take in consideration not only differences in species (rats vs. mice) but
194 also routes of administration. Compared to intraperitoneal administration, an oral dose has an
195 extra pass through the liver with consequent metabolism through the first-pass effect.

196

197 **Acute inflammation**

198 Acute inflammation has been commonly induced using carrageenan in animals in order to
199 evaluate the effects of non steroid anti-inflammatory drugs (NSAIDs)⁽⁵⁵⁾. We studied the effect
200 of hydroxytyrosol-supplemented OO on acute inflammation, induced by carrageenan in rats, at
201 0.5 and 5 mg/kg⁽⁴⁹⁾ dose, after gavage administration which occurred 30 min before the challenge
202 with carrageenan. Both doses significantly reduced paw edema ($p < 0.001$ vs. positive control)
203 with the lowest effective dose being achievable through OO daily intake. Previous studies in
204 rats⁽⁵⁶⁾ also showed inhibition of carrageenan - acute inflammation of an aqueous hydroxytyrosol
205 formulation (HT-20, 22% hydroxytyrosol), and significant effects were obtained at a 22 mg/kg
206 hydroxytyrosol dose. Differences in dose effect might be related to the administration vehicle
207 with ROO or OO being better vehicles than water.

208

209 **3. Cardioprotection of olive oil**

210 Most of the interventional studies focusing on the benefit of VOO intake on cardiovascular
211 disease have investigated the effect of phenolic compounds on the prevention of oxidation of
212 low-density (LDL) and high-density (HDL) lipoproteins⁽⁵⁷⁻⁶⁴⁾, two risk markers of cardiovascular
213 disease. A number of trials have also focused on cardioprotection against inflammation⁽⁶⁵⁾
214 mainly on antioxidant activity and inflammatory mediators.

215

216

217

218

219 **Impact of olive oil constituents on lipoproteins and atherosclerosis**

220

221 *Fat content*

222 LDL particles carry about two-thirds of plasma cholesterol and can infiltrate the arterial wall
223 attracting macrophages, smooth muscle cells, and endothelial cells⁽⁶⁶⁾ thus driving atherosclerosis.

224 LDL particle size is influenced by type and amount of dietary fat consumed⁽⁶⁷⁾: Low-fat diets

225 lead to a decrease in the size of LDL particles compared to high-fat diets⁽⁶⁸⁾. The type of fat

226 ingested is also important: LDL particles are larger with high-monounsaturated fatty acid diets

227 (such as those based on OO), compared to diets with a high polyunsaturated fatty acids intake,

228 where LDL particles are smaller⁽⁶⁹⁾. LDL particle size is especially relevant, since small size

229 particle are more prone to oxidation and can better enter into the arterial wall when compared

230 with larger LDL particles⁽⁷⁰⁾. Conversely, HDL particles are antiatherogenic, as their primarily

231 role is to deliver cholesterol to the liver to be metabolized and excreted or reused. HDL may also

232 be able to dislodge cholesterol molecules from atheromas in arterial walls⁽⁶⁶⁾. It has been

233 reported in patients with peripheral vascular disease^(71, 72), that LDL particles are less susceptible

234 to oxidation when the diet is enriched in VOO monounsaturated fatty acids, compared to the

235 polyunsaturated fatty acids of sunflower oil enriched diets. Moreover when compared to

236 saturated fatty acids intake, OO oleic acid reduces the level of LDL-cholesterol^(63, 64).

237 The health benefits associated with monounsaturated fat content in OO were recognised by the

238 United States Food and Drug Administration (FDA) in 2004, highlighting “the benefits on the

239 risk of coronary heart disease of eating about two tablespoons (23 g) of OO daily”⁽⁷³⁾. Health

240 benefits were related with a decrease of total and LDL cholesterol in serum⁽⁷³⁾, diet improvement

241 of endothelial dysfunction⁽⁷⁴⁾, coagulation activity⁽⁷⁵⁾ and reduced LDL susceptibility to

242 oxidation⁽⁷²⁾.

243

244 *Phenolic content*

245 Antioxidants that can prevent lipid peroxidation, such as phenolic compounds, could play an

246 important role in preventing oxidative modification of LDL⁽⁴⁾, with the oxidative process an

247 initiating factor for atherosclerotic plaques⁽⁷⁶⁾. Once monocytes differentiate in macrophages on

248 the endothelium they scavenge oxidized LDL (ox-LDL), then becoming foam cells, leading to

249 plaque formation⁽⁵⁾.

250 The Effect of Olive Oil on Oxidative Damage in European Populations (EUROLIVE) study was
251 a cross-over fat replacement intervention⁽⁵⁸⁾, using OOs with different phenolic content in
252 healthy male volunteers. Its findings led to the current EFSA recommendation (Opinion of the
253 Scientific Committee/Scientific Panel, *EFSA Journal*^(50, 77, 78)). A linear increase in HDL-
254 cholesterol levels after 3 weeks was observed after low-, medium-, and high-polyphenol OO
255 consumption: mean change from preintervention, 0.02 mmol/L (95% CI, 0.00 to 0.05 mmol/L),
256 0.03 mmol/L (95% CI, 0.00 to 0.05 mmol/L), and 0.04 mmol/L (95% CI, 0.02 to 0.06 mmol/L),
257 respectively. Total cholesterol:HDL cholesterol ratio decreased linearly with the phenolic
258 content of the OO. Triglyceride levels decreased by an average of 0.05 mmol/L for all OOs⁽⁵⁸⁾.
259 Mean changes from preintervention for ox-LDL levels were 1.21 U/L (95% CI, -0.8 to 3.6 U/L),
260 -1.48 U/L(95% CI, -3.6 to 0.6 U/L) and -3.21 U/L (95% CI, -5.1 to -0.8 U/L) for the low-,
261 medium-, and high-polyphenol OO, respectively, showing a dose-dependent relation with VOO
262 phenolic content⁽⁵⁸⁾. The EFSA confirmed a cause effect relationship between consumption of
263 OO phenolics (standardized by the content of hydroxytyrosol and its derivatives) and protection
264 of LDL cholesterol particles against oxidative damage. To support the EFSA health claim, 5 mg
265 of hydroxytyrosol and its derivatives should be consumed daily in 20 g OO⁽⁵⁰⁾, but
266 concentrations in some OOs may be too low to achieve this target in the context of a balanced
267 diet. Moreover, the EFSA Panel commented study design limitations as most human
268 interventions with OO have been conducted in more homogeneous male populations⁽⁷⁷⁾ and not
269 in general population.

270

271 The contribution of OO phenolics toward cardiovascular health benefits has been challenged
272 with inconsistent results reported for *ex vivo* resistance of LDL to oxidation^(79, 80). Seven human
273 intervention studies with OO were compared for impact of phenolics on ox-LDL, with no effect
274 seen in five of them⁽⁷⁹⁾, possibly explained by artifacts generated during LDL isolation.

275

276 Since the approval of the EFSA claim, both terminology and analytical methodology supporting
277 the dose calculation of hydroxytyrosol and derivatives have been appraised. Mastralexi *et al.*⁽⁸¹⁾
278 commented on the weaknesses of the claim terminology namely the term “olive oil polyphenols”
279 is not entirely clear and accurate as “olive oil” is a generic term for the type of oil, and the basic
280 structure of OO phenolic compounds do not coincide with a “polyphenolic” structure;
281 accordingly “virgin olive oil bioactive phenols” is a more appropriate term. Others also

282 commented about the lack of robust and reliable methods for quantifying phenolic compounds in
283 OO. A simple and robust method for routine analysis of hydroxytyrosol and tyrosol was
284 proposed^(81, 82) based on hydrolysis of the polar fraction of OO. This was followed by
285 development and validation of a ¹H NMR method enabling direct measurement of tyrosol and
286 hydroxytyrosol derivatives, as well as oleocanthal and oleacein in OO, overcoming analytical
287 issues such as chromatographic peak broadening⁽¹⁹⁾.

288

289 **Cardioprotective mechanisms of oleic acid**

290 OO intake has been related with a decrease on blood pressure with oleic acid regarded as being a
291 major contributor to this effect, as evidenced in animal models⁽⁸³⁾. Chronic oral administration of
292 VOO (rich in oleic acid), triolein (a triacylglyceride with three oleic acid moieties) or oleic acid
293 over 14 days significantly reduced systolic blood pressure in rats (-26 ± 4 for VOO and -21 ± 3
294 mm Hg for triolein, $p < 0.001$, and -17 ± 1.9 mm Hg for oleic acid $p < 0.05$) when compared to the
295 control group that received water. Similarly acute (2 h) treatments with either VOO or triolein
296 also significantly reduced systolic blood pressure when compared to the control group
297 (-20 ± 0 mm Hg, $p < 0.001$, and -14 ± 2 mm Hg, respectively, $p < 0.05$) with oleic acid again
298 significantly reducing systolic blood pressure (-13.0 ± 0.3 mm Hg; $p < 0.001$). In contrast,
299 chronic treatment with the trans-monounsaturated fatty acid elaidic (18:1n-9) or the saturated
300 fatty acid stearic acid (18:0) did not significantly affect blood pressure. Results show that
301 saturation and cis/trans double bond arrangement are implicated with the cardioprotective effect
302 of the long chain fatty acid in this animal model at high dose levels⁽⁸³⁾. Similar significant results
303 were obtained after VOO and oleic acid intake in an animal model of hypertension using
304 spontaneously hypertensive rats⁽⁸³⁾.

305 The molecular mechanisms were evaluated by measuring signaling proteins involved in the
306 control of blood pressure in the aorta. OO intake increases oleic acid levels in membranes, which
307 regulate membrane lipid structure and impact on G protein-mediated signaling, causing a
308 reduction in blood pressure⁽⁸⁴⁾. Unlike its analogues elaidic and stearic acid, oleic acid, due to its
309 cis-18:1n-9 structure, regulates cellular membrane lipid structure and the α_2 receptor system
310 involved in the control of blood pressure ($\alpha_{2A/D}$ - adrenoreceptor/G protein/adenylyl cyclase-
311 cAMP/PKA) as demonstrated *in vitro*⁽⁸⁴⁾ and *in vivo*⁽⁸³⁾. Oleic acid can also contribute to heart
312 health via intramyocardial triglyceride turnover⁽⁸⁵⁾, which is reduced in pressure-overloaded
313 failing hearts. In this situation oleate (derivative of oleic acid) upregulated triglyceride dynamics

314 when compared to palmitate (derivative of palmitic acid and major saturated fatty acid of palm
315 oil). This result underscores the importance of the intracellular lipid storage type on nuclear
316 receptor signaling and contractility⁽⁸⁵⁾ in diseased hearts.

317 An important driver of vasorelaxation is nitric oxide, a free radical which readily reacts with fats
318 and proteins. Nitro-fatty acids are mediators of cardiovascular signaling actions⁽⁸⁶⁾ as these
319 compounds relax blood vessels, attenuate platelet activation, and reduce inflammation^(87, 88).

320 Both oleic acid and linoleic acid are unsaturated fatty acids that after reaction with nitrite may
321 form nitro-fatty acids. Nitro-oleic acid mediated antihypertensive signaling actions were shown
322 in a mouse model⁽⁸⁹⁾. The mechanism was attributed to the inhibition of soluble epoxide
323 hydrolase by nitro-fatty acids, thus lowering blood pressure in an angiotensin II-induced
324 hypertension⁽⁸⁹⁾. It is however unclear how the extent of nitrite in the human diet may contribute
325 to nitration of dietary fat, and the physiological relevance of this finding.

326

327 **Role of phenolic compounds on endothelium protection**

328 Oxidative stress and reactive oxygen species (ROS) have been implicated in endothelial damage,
329 progression to atherosclerosis, injury in sustained myocardial infarction and ischemia
330 reperfusion^(76, 90-92). Monocytes and macrophages are critical cells that are involved in
331 atherosclerosis. These cells produce proinflammatory cytokines, such as IL-1 β , TNF- α and
332 C-reactive protein (CRP), which induce the expression of adhesion molecules like intercellular
333 adhesion molecule-1 (ICAM-1), vascular-cell adhesion molecule-1 (VCAM-1), and E-selectin⁽⁹³⁾.
334 Meanwhile, oxidative stress through ROS production promotes the expression of the adhesion
335 molecules on the endothelium⁽⁹⁴⁾.

336 Expression of adhesion molecules attracts circulating monocytes inducing their adherence to the
337 endothelium. OO phenolic compounds have been shown to act on endothelium protection as
338 evidenced in *in vitro* assays with typical OO phenolic compounds and less on *in vivo* circulating
339 metabolites. OO phenolic extract, oleuropein aglycone or homovanillic alcohol (metabolite of
340 hydroxytyrosol) had inhibitory effects on VCAM-1, ICAM-1 and E-selectin surface expression
341 in human umbilical vascular endothelial cells, using TNF- α as pro-inflammatory stimulus⁽⁹⁵⁾.

342

343 Endothelium dysfunction refers to an impairment of endothelium-dependent vasorelaxation
344 caused by a loss of NO bioactivity in the vessel wall. In animal models with rats oral
345 hydroxytyrosol administration was tested on NO production and platelet function⁽⁹⁶⁾. Results

346 showed that hydroxytyrosol administration (100 mg/kg/day) increased vascular NO production
347 by up to 34.2% ($p < 0.01$) and inhibited platelet aggregation for 50% inhibitory dose of
348 48.25 mg/day for hydroxytyrosol ($p < 0.01$) when compared to control group (treated with
349 isotonic saline solution). Animal dose translation to humans allowed us to conclude that the
350 effective hydroxytyrosol doses tested would be above the expected intake through OO daily. The
351 reported benefits would only be achievable through nutraceutical supplementation.

352

353 **Endothelium repair: matrix metalloproteinases and olive oil**

354 Matrix metalloproteinases (MMPs) play a role in endothelium repair. Macrophages resident in
355 human and experimental atherosclerosis co-localize with and release active MMPs including the
356 gelatinase MMP-9, which is specialized in the digestion of basement membrane collagens and
357 elastin, and is implicated in atherogenesis, unstable coronary syndromes, and in aortic
358 aneurysms⁽⁹⁷⁾. Accumulating evidence points to the MMPs as major molecular mediators of
359 arterial diseases⁽⁹⁷⁾. Collagens, types 1 and 3, are the main proteins in arterial walls being also
360 present in the thickened intima of atherosclerotic lesions^(98, 99). Fragments of collagens found in
361 urine are present as a result of proteolytic activity in arterial walls and other vascular structures.
362 Collagen type 1 or 3 fragments were up-regulated in urine in coronary artery disease (CAD)
363 patients⁽¹⁰⁰⁾. Increase in collagen degradation is related with an increase on collagenases
364 circulation, such as MMP-9, as shown in patients with CAD⁽¹⁰¹⁾.

365 In an *in vitro* study hydroxytyrosol (1-10 μ M) reduced MMP-9 ($IC_{50} = 10 \mu$ mol/L, $p < 0.05$) and
366 COX-2 induction in activated human monocytes, with phorbol myristate acetate (PMA)⁽¹⁰²⁾.
367 These effects were mediated by inhibition of transcription factor NF- κ B and protein kinase C
368 (PKC) α and PKC β 1 activation⁽¹⁰²⁾. Results are in line with previous *in vitro* reports that showed
369 inhibition of MMP-9 on endothelial cells by OO phenolics namely hydroxytyrosol in PMA
370 induced cells⁽¹⁰³⁾, and oleuropein aglycone in TNF- α induced cells by acting on NF- κ B⁽⁹⁴⁾. No
371 hydroxytyrosol activity on MMP-9 was found in TNF- α induced cells⁽⁹⁴⁾.

372 The discriminatory polypeptides that increase in CAD includes collagen type 1 and 3 fragments
373 with a C-terminal GxPGP motif⁽¹⁰⁴⁾. Increase on these polypeptides would come from a protease
374 decrease activity possibly related with chemical change of the substrate (e.g.: oxidative damage)
375 thus inhibiting it acting at a specific site, or a decrease in circulating levels by lack of enzyme
376 activation. MMP-2 is secreted in an inactive form (pro MMP-2) and several factors can promote

377 its activation such as plasmin⁽¹⁰⁵⁾ and thrombin⁽¹⁰⁶⁾. Other mechanisms that involve proteinases or
378 oxidative stress can also activate MMP-2⁽¹⁰⁷⁾. Therefore antioxidants, as phenolic compounds,
379 might have a role on MMP-2 activation and published data indicate phenolic compounds from
380 red wine⁽¹⁰⁸⁾ and green tea⁽¹⁰⁹⁾ as acting on prevention of thrombin-induced activation of MMP-2
381 in vascular smooth cells.

382

383 We evaluated the impact of a 6-week OO supplementation in healthy adults on urinary proteomic
384 biomarkers of CAD in a randomized, parallel, controlled, double-blind study⁽¹¹⁰⁾. This study was
385 the first to describe the significant impact of daily OO supplementation on highly specific
386 disease biomarkers for CAD. Analysis of urinary proteomic profiles at baseline and endpoint
387 enabled the identification of 12 sequenced peptides that were significantly regulated toward
388 healthy scoring. Eight of them included four collagen α -1(I) chain, one α -2 (1) chain, one α -2(V)
389 chain, and one α -2(VI) chain fragments. Changes in circulating concentrations of collagenases
390 may mediate these changes in the urinary fingerprint. Therefore with more data or in future
391 intervention studies with OO it would be interesting to link urinary fragments to the proteases
392 involved in their generation. This predictive analysis would enable looking at the peptide
393 cleavage sites studying the MMPs up or downregulated with OO intervention.

394

395 The majority of studies of dietary intake of proposed bioactive foods assess the activities of these
396 foods based on the major risk factors of cardiovascular disease. However marker such as
397 lipoprotein profile, blood pressure, endothelial function, inflammation and oxidative stress have
398 no direct link to the disease itself but are merely associated with it. There is a great need for more
399 biomarkers that appear as a direct result of the disease itself^(63, 67).

400

401

402 **4. Proteomics biomarkers as a mechanistic approach to explain olive oil health effects**

403 The systems biology approach (encompassing genomics, transcriptomics, proteomics and
404 metabolomics using urine, blood or saliva) could provide a greater understanding of disease
405 development, treatment efficacy and evaluation of the influence of food bioactive
406 compounds^(46, 111). There is a need for biomarkers of practical value for clinical intervention,
407 allowing disease risk prediction and more importantly early diagnosis. Accuracy, reproducibility,
408 availability, feasibility of implementation into the clinical settings, sensitivity and specificity are
409 additional characteristics to be fulfilled, and panels of biomarkers are gaining acceptance instead
410 of individual molecules⁽¹¹²⁾, as single biomarkers are often not available and lack the ability to
411 adequately describe complex diseases⁽¹¹³⁾. Candidate biomarkers should be carefully validated in
412 a wide and different cohort of samples from those used in the discovery phase as often
413 overfitting of the biomarker model has occurred⁽¹¹⁴⁾.

414 The proteome, corresponding to a set of expressed proteins, informs the current “status” of an
415 organism, constantly changing according to endogenous and exogenous factors⁽¹¹³⁾. Proteins are
416 widely used in different clinical tests for both diagnosis and prognosis of diseases and to follow
417 their evolutions⁽⁹⁸⁾. They can be used to measure the extent of inflammation, calcification, and
418 the development of plaques on the arteries. Understanding what causes plaque rupture is of great
419 importance. As previously mentioned, MMPs could have a key role in this process⁽¹¹⁵⁾. The
420 discovery of proteomic biomarkers may be useful in understanding the molecular mechanisms
421 involved in the onset and progression of other vascular diseases⁽¹¹⁶⁾. Plasma, serum and urine are
422 the most commonly used biological matrices in cardiovascular research, due to their perceived
423 clinical relevance as a source of potential biomarkers⁽⁹⁸⁾. However proteomic studies have also
424 been carried out on vascular tissues (arteries), artery layers, cells looking at proteomes and
425 secretomes, exosomes, lipoproteins, and metabolites⁽⁹⁸⁾. Although sampling the tissue may seem
426 an obvious method there are a number of difficulties, especially where the need for a biopsy
427 would be required⁽¹¹⁷⁾. Recent advances in extraction processes and LC-MS/MS analysis has
428 allowed the quantitative analysis of tissue samples in vascular research to be carried
429 out^(118, 119).

430 Urine, as a sample source is now recognized as the source of choice for proteomic biomarker
431 investigations. It has a number of advantages such as being noninvasive and can be collected by
432 untrained personnel. Urine is produced by renal filtration of the plasma and approximately 70%

433 of proteins in the normal human urinary proteome are of kidney origin, whereas the remaining
434 30% are derived from plasma proteins^(120, 121). It has high stability due to absence of proteolytic
435 agents and the low dynamic range of analyte concentration facilitates the detection and
436 quantification of peptides^(113, 122).

437 Using capillary electrophoresis coupled with mass spectrometry (CE-MS)⁽¹²³⁾ urinary biomarker
438 classifiers for the diagnosis of diseases like chronic kidney disease⁽¹²⁴⁾, acute kidney injury⁽¹²⁵⁾,
439 stroke⁽¹²⁶⁾, and coronary artery diseases⁽¹⁰⁴⁾, were already identified, allowing classification of
440 case *versus* control groups with good accuracy⁽¹²⁷⁾.

441 Urinary peptides and protein fragments are the end products of proteolytic processes. The
442 different pattern of urinary excretion of peptides when comparing controls and disease patients
443 might indicate their role in the pathophysiology of disease. Therefore changes in the normal
444 urine "fingerprint" (e.g.: presence of collagen fragments) can be used as biomarkers of disease.
445 Besides collagens, common blood proteins (e.g., alpha-1-antitrypsin, hemoglobin, serum
446 albumin, and fibrinogen), and uromodulin were also identified⁽¹²⁸⁾ in urine which provides
447 additional proof of the suitability of this sample source for proteomic biomarker studies out with
448 the kidney and urinary tract. Collagens are the most abundant peptides sequenced so far in the
449 CAD biomarker (66% of all peptides)⁽¹⁰⁴⁾, with atherosclerosis associated with an increased
450 synthesis of several extracellular matrix components, including collagen types 1 and 3, elastin,
451 and several proteoglycans⁽¹²⁹⁾. Changes in the circulating levels of collagenases may mediate
452 these changes in peptides represented in the fingerprint, as reported in coronary
453 atherosclerosis⁽¹⁰⁰⁾, and chronic kidney disease⁽¹²⁸⁾.

454 The progress in urinary proteomics and the use of multiple biomarker classifiers opens the
455 possibility of establishing new tools adapted to different clinical needs⁽¹³⁰⁾, enabling direct
456 monitoring of disease overcoming limitations of indirect measurements.

457

458 **Proteomic *in vitro* studies on olive oil phenolic compounds**

459 Proteomics has been applied in a number of studies of OO phenolic compounds on
460 cardiovascular health using animal and *in vitro* studies. The *in vitro* effects of alperujo extract, an
461 OO production waste product containing phenolic compounds present in olive fruits, were
462 studied on platelet aggregation and changes in the platelet proteome⁽¹³¹⁾. Nine proteins were
463 differentially regulated by the alperujo extract upon platelet aggregation underlying the anti-

464 platelet effects of the extract. However, like a number of previously mentioned *in vitro* studies,
465 the effective concentrations (40-500 mg/L) were far above the physiologically concentrations
466 achievable by dietary intake.

467 The effects of EVOOs, with low and high in phenolic content, were evaluated in the hepatic
468 proteome in Apoe^{-/-} mice that spontaneously develop atherosclerosis⁽¹³²⁾. For 10 weeks the mice
469 were fed with a high fat high cholesterol diet supplemented with 0.15% (w/w) cholesterol and
470 either 20% (w/w) low phenolic EVOO or 20% (w/w) high phenolic EVOO *versus* a control
471 group fed with 0.15% (w/w) cholesterol and 20% (w/w) palm oil. Within this work a range of
472 hepatic antioxidant enzymes differentially regulated by OO⁽¹³²⁾ were identified. The authors
473 concluded that the up-regulation of a large array of antioxidant enzymes might explain anti-
474 atherogenic mechanisms of EVOOs⁽¹³²⁾. Again the dose level was above what could be achieved
475 through dietary intake and translation from an animal model to human has also to be considered.

476

477 **Urinary proteomics biomarkers, olive oil and cardiovascular disease**

478 Atherosclerosis is a process of chronic inflammation, characterized by the accumulation of
479 lipids, cells, and fibrous elements in medium and large arteries⁽⁹⁸⁾. The extent of
480 inflammation, proteolysis, calcification, and neovascularization influences the development of
481 advanced lesions (atheroma plaques) on the arteries⁽⁹⁸⁾.

482 Classical risk factors in atherosclerosis (hypertension, LDL-cholesterol, C-reactive protein,
483 aging, smoking, male gender, among others) do not actually measure disease initiation or
484 progression. As such, they cannot be used directly to identify individuals who have developed
485 atherosclerosis and prevent a fatal event^(98, 133). Other, more recent markers that indicate changes
486 in vascular structure can still only be detected once cardiovascular disease has progressed to an
487 advanced stage where drug or surgical intervention is required⁽¹³⁴⁾.

488 The analysis of urine samples from diseased and healthy individuals has been used to establish a
489 database of naturally occurring urinary peptides, making a basis for the definition and validation
490 of biomarkers for diagnosis/prognosis/monitoring of a wide range of diseases using proteomic
491 biomarker patterns⁽¹²⁸⁾, such as CAD⁽¹⁰⁰⁾, emphasizing that non-invasive proteomics analysis
492 could become a valuable addition to assess cardiovascular disease alongside to other biomarkers
493 which are indicators of cardiovascular risk.

494 The first time that urinary proteomics was applied to assess cardiovascular health improvements
495 of OO consumption in humans, was in a randomized, parallel, controlled, double-blind study
496 designed to evaluate the impact of a 6 week OO supplementation in healthy adults on urinary
497 proteomic biomarkers of CAD⁽¹¹⁰⁾. The impact of the supplementation with OO was also studied
498 on urinary proteomic biomarkers of chronic kidney disease (CKD), and diabetes.

499 The increase or decrease in the concentration of the peptides in the biomarker determines the
500 scoring value of each disease biomarker. The CAD proteomic biomarker developed for clinical
501 diagnosis produces a CAD scoring system from 1 (CAD case) to -1 (healthy artery). A scoring of
502 disease absence, presence and severity is provided, based on the concentration of a group (panel)
503 of urinary peptides measured by CE-MS, allowing monitoring of progression and/or effect of
504 treatment^(135, 136). In this study, self-reported healthy participants were randomly allocated to
505 supplementation with a daily dose of OO either low or high in phenolic compounds. For 6
506 weeks, they consumed a daily dose of 20 mL OO (not heated or cooked) as a supplement (no
507 specific time during the day, single intake, equivalent to 6 mg of hydroxytyrosol and derivatives
508 for the high phenolic OO), in line with the EFSA and FDA recommendations. The impact of
509 supplementation with OO was evaluated on urinary proteomic biomarkers of CAD with
510 biomarkers being measured at baseline and 3 and 6 weeks. Consumption of both OOs
511 significantly improved the proteomic CAD score at endpoint compared with baseline, moving
512 the CAD biomarker pattern in a healthy profile direction, **Table 2**. No differences were observed
513 for CKD or diabetes proteomic biomarkers, Table 2.

514 In a placebo-controlled intervention, Irbesartan (angiotensin II receptor antagonist used for the
515 treatment of hypertension) taken at 300 mg per day over 2 years in hypertensive type 2 diabetes
516 patients, using the CAD 238 biomarker panel, led to a 0.35 point reduction in the CAD score for
517 the drug-controlled group⁽¹⁰⁴⁾, which saw a significant reduction in incidents of CAD in this
518 group. In the nutritional intervention⁽¹¹⁰⁾ the CAD score change in the intervention was
519 significant for both OOs tested, using the same CAD 238 biomarker, leading to a similar degree
520 of change as observed for irbersartan over a 6 week period. This evidence highlights the
521 importance of the CAD biomarker as a tool for nutrition and health intervention studies. This
522 type of urinary biomarker enabled the measurement of health effects induced by a change in diet
523 that could not be detected by monitoring the conventional risk markers of CAD such as plasma
524 triacylglycerols, oxidized LDL, and LDL cholesterol. The overall change in CAD score in a

525 short period of time is more likely due to OO major components, such as fatty acids. However
526 the role of other OO minor components other than phenolic compounds should also be taken into
527 account. Squalene, a polyunsaturated triterpene which makes up 60–75% of the unsaponifiable
528 fraction of OO⁽¹³⁷⁾, reduced atherosclerotic lesion size in male mice⁽¹³⁸⁾ and further investigation
529 is needed to clarify its role on cardiovascular disease.

530

531 Our results emphasize further the potential role of nutrition in the prevention or delay of
532 cardiovascular disease and offer new perspectives on OO applications. These results are highly
533 translatable to guidelines for nutritional recommendations. The biomarkers were originally
534 developed to detect early signs of diseases in clinical setting and to inform clinician as to the
535 effectiveness of treatment. However, the technology also provides a sensitive tool for the
536 assessment of potential bioactive foods in cardiovascular health, chronic kidney disease and
537 diabetes, with a range of additional tests under development. Further testing of reportedly
538 bioactive foods can now be carried out which will allow better nutritional health advice to be
539 advanced and could also lead to better food labeling so that the public can make informed
540 choices on their food purchases.

541

5. Exploring olive oil health benefits: perspectives

Although strong evidence from heritability is related with cardiovascular disease many forms of heart disease are not genome associated⁽¹³⁹⁾. The epigenome is a possible link between genetics and environment⁽¹³⁹⁾ which includes impact of food components/diet. Omics techniques (genomics, transcriptomics, proteomics, epigenomics, metabolomics) have the potential, when integrated, to paint a comprehensive picture of the contribution of diet toward the modulation of disease risk⁽¹⁴¹⁾. Some trials have shown the impact of OO on down-regulation of atherosclerosis-related genes^(140, 141). The effect of Mediterranean Diet was studied on urinary metabolome⁽¹⁴²⁾ and related to compounds of the metabolism of carbohydrates, creatine, creatinine, amino acids, lipids and microbial cometabolites.

Phenolic compounds can interact with cellular signaling cascades regulating the activity of transcription factors with impact on gene expression. For instance, phenolic compounds have shown to affect the expression of microRNAs (miRNA)⁽¹⁴³⁾. miRNAs are small, noncoding RNAs implicated in the regulation of gene expression that control both physiological and pathological processes, influenced by external factors as diet components⁽¹⁴⁴⁾. Most of the studies reported in this field are *in vitro* and more *in vivo* studies are needed to clarify miRNA targets of dietary phenolic compounds⁽¹⁴⁴⁾.

Interactions between genes and the bioactive components present in OO studied by nutrigenomics may help to explain its health benefits⁽¹⁴⁵⁾. In this sense, besides their antioxidant and anti-inflammatory capacities, OO phenolic compounds are able to modify gene expression coding in a protective mode for proteins participating in the cellular mechanisms involved in oxidative stress resistance, inflammation or lipid metabolism amongst others⁽¹⁴⁶⁾.

Glycation, a non-enzymatic reaction between reducing sugars and proteins, is a proteome wide phenomenon, mainly observed in diabetes due to hyperglycemia⁽¹⁴⁷⁾, but also relevant to end organ damage, disease pathogenesis and aging⁽¹⁴⁸⁾ and OO phenolic compounds have been reported as potent inhibitors of the formation of advanced glycation end products⁽¹⁴⁹⁾. Our human intervention trial with OO low or high in phenolics did not find a significant impact on plasma fructosamine levels⁽¹¹⁰⁾. A key factor may be the duration of the study (6 weeks) not being sufficient to detect changes in protein modifications such as glycation, and may also be partly related to the quantity and quality of phenolic compounds, which exert differential antioxidant and antiglycative activities depending on structure^(4, 150). Further studies should proceed in

order to clarify anti-glycation properties of OO phenolic compounds, given that glycation is a key driver for tissue damage and is present in all non-communicable disease scenarios.

6. Conclusion

Results outlined in this review provide evidence of health benefits related with OO intake. The reported studies may allow the implementation of primary prevention programs of cardiovascular disease, based on nutritional interventions, useful in non-regular OO consumers groups like the Northern European populations. Interventions in broad populations with highly specific disease biomarkers, as urinary proteomic biomarkers, will offer higher translational value, especially toward development and implementation of new nutritional recommendations. Human intervention trials focusing on new outcomes related with proteomics and nutrigenomics are needed to better clarify pathways/mechanisms by which oleic acid, phenolic compounds or even other OO components act on cardiovascular disease risk factors and affect the proteome.

7. Financial Support


QREN project Azeite+ Global nº 12228 and Ordem dos Farmacêuticos (Lisbon, Portugal).

8. Conflict of Interest

Conflict of interest: Thomas Koeck is employed at Mosaiques Diagnostics, the company that developed the urinary proteomics for CE-MS technology for clinical application. No other authors declare a conflict of interest.


Table 1 – Main classes of phenolic compounds in virgin olive oil

Phenolic acids




Caffeic acid

Phenolic alcohols




Hydroxytyrosol




Tyrosol

Flavonoids




Luteolin

Lignans




(+) - Pinoresinol


Secoiridoids



**Oleuropein aglycone
(3,4-DHPEA-EA)**



**Ligstroside aglycone
(*p*-HPEA-EA)**



**Dialdehydic form of deacetoxy
oleuropein (3,4-DHPEA-EDA)**

Table 2 Changes in scores of CAD, CKD and diabetes proteomic biomarkers at baseline, middle (3-weeks) and end of intervention (6 weeks)¹

		Low phenolic olive oil (n = 34)	High phenolic olive oil (n = 28)
		Score	Score
CAD proteomic biomarker	baseline	-0.5 ± 0.2	-0.6 ± 0.4
	3 weeks	-0.7 ± 0.3	-0.7 ± 0.3
	6 weeks	-0.8 ± 0.3**	-0.8 ± 0.3*
CKD proteomic biomarker	baseline	-0.4 ± 0.2	-0.4 ± 0.3
	3 weeks	-0.4 ± 0.2	-0.4 ± 0.3
	6 weeks	-0.4 ± 0.2	-0.4 ± 0.2
Diabetes proteomic biomarker	baseline	1.3 ± 0.3	1.3 ± 0.3
	3 weeks	1.3 ± 0.4	1.3 ± 0.3
	6 weeks	1.4 ± 0.4	1.2 ± 0.3

¹Values are means ± SDs; 95% CIs in parentheses. A repeated-measures ANOVA test was used with statistical significance at $p < 0.05$. ***Compared with corresponding baseline value: * $p < 0.005$, ** $p < 0.001$. There were no significant differences in changes between groups. CAD, coronary artery disease; CKD, chronic kidney disease (adapted from Silva *et al.*⁽¹⁰⁴⁾).

REFERENCES

1. Obied HK, Prenzler PD, Ryan D, Servili M, Taticchi A, Esposto S, et al. Biosynthesis and biotransformations of phenol-conjugated oleosidic secoiridoids from *Olea europaea* L. *Natural product reports*. 2008;25(6):1167-79.
2. European Commission, Official Journal of the European Union, 27.1.2011, Commission Regulation (EC) No 61/2001 of 24 January 2011
3. European Commission, Official Journal of the European Union, 5.7.2008, Commission Regulation (EC) No 640/2008 of 4 July 2008.
4. Tripoli E, Giammanco M, Tabacchi G, Di Majo D, Giammanco S, La Guardia M. The phenolic compounds of olive oil: structure, biological activity and beneficial effects on human health. *Nutrition research reviews*. 2005;18(1):98-112.
5. Covas MI. Olive oil and the cardiovascular system. *Pharmacological research : the official journal of the Italian Pharmacological Society*. 2007;55(3):175-86.
6. Lopez-Miranda J, Perez-Jimenez F, Ros E, De Caterina R, Badimon L, Covas MI, et al. Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2010;20(4):284-94.
7. Urpi-Sarda M, Casas R, Chiva-Blanch G, Romero-Mamani ES, Valderas-Martinez P, Arranz S, et al. Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory biomarkers related to atherosclerosis. *Pharmacological research : the official journal of the Italian Pharmacological Society*. 2012;65(6):577-83.
8. Martinez-Lapiscina EH, Clavero P, Toledo E, San Julian B, Sanchez-Tainta A, Corella D, et al. Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial. *The journal of nutrition, health & aging*. 2013;17(6):544-52.
9. Kastorini CM, Milionis HJ, Goudevenos JA, Panagiotakos DB. Mediterranean diet and coronary heart disease: is obesity a link? - A systematic review. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2010;20(7):536-51.
10. Razquin C, Martinez JA, Martinez-Gonzalez MA, Mitjavila MT, Estruch R, Marti A. A 3 years follow-up of a Mediterranean diet rich in virgin olive oil is associated with high plasma antioxidant capacity and reduced body weight gain. *European journal of clinical nutrition*. 2009;63(12):1387-93.
11. Schwingshackl L, Hoffmann G. Mediterranean dietary pattern, inflammation and endothelial function: a systematic review and meta-analysis of intervention trials. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2014;24(9):929-39.
12. Schwingshackl L, Hoffmann G. Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. *Lipids in health and disease*. 2014;13:154.
13. Harwood J. AR. *Handbook of olive oil analysis and properties* 2000.
14. Servili M, Montedoro, G. . Contribution of phenolic compounds to virgin olive oil quality. *European Journal of Lipid Science and Technology*. 2002;104:602-13.
15. Perez-Jimenez F, Ruano J, Perez-Martinez P, Lopez-Segura F, Lopez-Miranda J. The influence of olive oil on human health: not a question of fat alone. *Molecular nutrition & food research*. 2007;51(10):1199-208.

- 46 16. Di Maio I, Esposto, S., Taticchi, A., Selvaggini, R., Veneziani, G., Urbani, S. , Servili, M.
47 . HPLC–ESI-MS investigation of tyrosol and hydroxytyrosol oxidation products in virgin olive
48 oil. *Food Chemistry*. 2011;125:21-8.
- 49 17. Brenes M, Garcia A, Garcia P, Garrido A. Acid hydrolysis of secoiridoid aglycons during
50 storage of virgin olive oil. *Journal of agricultural and food chemistry*. 2001;49(11):5609-14.
- 51 18. Hrnčirik K. F, S. . Comparability and reliability of different techniques for the
52 determination of phenolic compounds in virgin olive oil. *European Journal of Lipid Science and*
53 *Technology*. 2004;106:540-9.
- 54 19. Karkoula E, Skantzari A, Melliou E, Magiatis P. Direct measurement of oleocanthal and
55 oleacein levels in olive oil by quantitative (1)H NMR. Establishment of a new index for the
56 characterization of extra virgin olive oils. *Journal of agricultural and food chemistry*.
57 2012;60(47):11696-703.
- 58 20. Corona G, Tzounis X, Assunta Dessi M, Deiana M, Debnam ES, Visioli F, et al. The fate
59 of olive oil polyphenols in the gastrointestinal tract: implications of gastric and colonic
60 microflora-dependent biotransformation. *Free radical research*. 2006;40(6):647-58.
- 61 21. Pinto J, Paiva-Martins F, Corona G, Debnam ES, Jose Oruna-Concha M, Vauzour D, et
62 al. Absorption and metabolism of olive oil secoiridoids in the small intestine. *The British journal*
63 *of nutrition*. 2011;105(11):1607-18.
- 64 22. Aranzazu Soler MPR, Alba Macià, Shikha Saha, Caroline S.M. Furniss, Paul A. Kroon,
65 Maria J. Motilva. Digestion stability and evaluation of the metabolism and transport of olive oil
66 phenols in the human small-intestinal epithelial Caco-2/TC7 cell line. *Food Chemistry*.
67 2010;119:703-14.
- 68 23. Vissers MN, Zock PL, Roodenburg AJ, Leenen R, Katan MB. Olive oil phenols are
69 absorbed in humans. *The Journal of nutrition*. 2002;132(3):409-17.
- 70 24. Garcia-Villalba R, Carrasco-Pancorbo A, Nevedomskaya E, Mayboroda OA, Deelder
71 AM, Segura-Carretero A, et al. Exploratory analysis of human urine by LC-ESI-TOF MS after
72 high intake of olive oil: understanding the metabolism of polyphenols. *Analytical and*
73 *bioanalytical chemistry*. 2010;398(1):463-75.
- 74 25. Mateos R, Goya L, Bravo L. Metabolism of the olive oil phenols hydroxytyrosol, tyrosol,
75 and hydroxytyrosyl acetate by human hepatoma HepG2 cells. *Journal of agricultural and food*
76 *chemistry*. 2005;53(26):9897-905.
- 77 26. Miro-Casas E, Covas MI, Farre M, Fito M, Ortuno J, Weinbrenner T, et al.
78 Hydroxytyrosol disposition in humans. *Clinical chemistry*. 2003;49(6 Pt 1):945-52.
- 79 27. Miro Casas E, Farre Albadalejo M, Covas Planells MI, Fito Colomer M, Lamuela
80 Raventos RM, de la Torre Fornell R. Tyrosol bioavailability in humans after ingestion of virgin
81 olive oil. *Clinical chemistry*. 2001;47(2):341-3.
- 82 28. Garcia-Villalba R, Larrosa M, Possemiers S, Tomas-Barberan FA, Espin JC.
83 Bioavailability of phenolics from an oleuropein-rich olive (*Olea europaea*) leaf extract and its
84 acute effect on plasma antioxidant status: comparison between pre- and postmenopausal women.
85 *European journal of nutrition*. 2014;53(4):1015-27.
- 86 29. Suarez M, Valls RM, Romero MP, Macia A, Fernandez S, Giralt M, et al. Bioavailability
87 of phenols from a phenol-enriched olive oil. *The British journal of nutrition*. 2011;106(11):1691-
88 701.
- 89 30. Preedy V.R. WRR. *Olives and olive oil in health and disease prevention*. 1st ed2010.

- 90 31. Tuck KL, Freeman MP, Hayball PJ, Stretch GL, Stupans I. The in vivo fate of
91 hydroxytyrosol and tyrosol, antioxidant phenolic constituents of olive oil, after intravenous and
92 oral dosing of labeled compounds to rats. *The Journal of nutrition*. 2001;131(7):1993-6.
- 93 32. Gonzalez-Santiago M, Fonolla J, Lopez-Huertas E. Human absorption of a supplement
94 containing purified hydroxytyrosol, a natural antioxidant from olive oil, and evidence for its
95 transient association with low-density lipoproteins. *Pharmacological research : the official
96 journal of the Italian Pharmacological Society*. 2010;61(4):364-70.
- 97 33. Visioli F, Galli C, Grande S, Colonnelli K, Patelli C, Galli G, et al. Hydroxytyrosol
98 excretion differs between rats and humans and depends on the vehicle of administration. *The
99 Journal of nutrition*. 2003;133(8):2612-5.
- 100 34. Mosele JI, Martin-Pelaez S, Macia A, Farras M, Valls RM, Catalan U, et al. Faecal
101 microbial metabolism of olive oil phenolic compounds: in vitro and in vivo approaches.
102 *Molecular nutrition & food research*. 2014;58(9):1809-19.
- 103 35. Khymenets O, Fito M, Tourino S, Munoz-Aguayo D, Pujadas M, Torres JL, et al.
104 Antioxidant activities of hydroxytyrosol main metabolites do not contribute to beneficial health
105 effects after olive oil ingestion. *Drug metabolism and disposition: the biological fate of
106 chemicals*. 2010;38(9):1417-21.
- 107 36. Tuck KL, Hayball PJ, Stupans I. Structural characterization of the metabolites of
108 hydroxytyrosol, the principal phenolic component in olive oil, in rats. *Journal of agricultural and
109 food chemistry*. 2002;50(8):2404-9.
- 110 37. Kotronoulas A, Pizarro N, Serra A, Robledo P, Joglar J, Rubio L, et al. Dose-dependent
111 metabolic disposition of hydroxytyrosol and formation of mercapturates in rats. *Pharmacological
112 research : the official journal of the Italian Pharmacological Society*. 2013;77:47-56.
- 113 38. Laura Rubió AS, Alba Macià, Carme Piñol, Maria-Paz Romero, Maria-José Motilva. In
114 vivo distribution and deconjugation of hydroxytyrosol phase II metabolites in red blood cells: A
115 potential new target for hydroxytyrosol. *Journal of functional foods*. 2014;10:139-43.
- 116 39. Hamden K, Allouche N, Damak M, Elfeki A. Hypoglycemic and antioxidant effects of
117 phenolic extracts and purified hydroxytyrosol from olive mill waste in vitro and in rats.
118 *Chemico-biological interactions*. 2009;180(3):421-32.
- 119 40. Sanchez de Medina V, Priego-Capote F, Luque de Castro MD. Characterization of
120 refined edible oils enriched with phenolic extracts from olive leaves and pomace. *Journal of
121 agricultural and food chemistry*. 2012;60(23):5866-73.
- 122 41. Suarez M, Romero MP, Motilva MJ. Development of a phenol-enriched olive oil with
123 phenolic compounds from olive cake. *Journal of agricultural and food chemistry*.
124 2010;58(19):10396-403.
- 125 42. Pashkow FJ. Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have
126 a Role in Treatment and/or Prevention? *International journal of inflammation*.
127 2011;2011:514623.
- 128 43. Vlantis K, Pasparakis M. Role of TNF in pathologies induced by nuclear factor kappaB
129 deficiency. *Current directions in autoimmunity*. 2010;11:80-93.
- 130 44. Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, et al. Phytochemistry:
131 ibuprofen-like activity in extra-virgin olive oil. *Nature*. 2005;437(7055):45-6.
- 132 45. Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, et al. Ibuprofen-like activity in
133 extra-virgin olive oil. *Nature*. 2005;437(7055):45-6.
- 134 46. Tulp M, Bruhn JG, Bohlin L. Food for thought. *Drug discovery today*. 2006;11(23-
135 24):1115-21.

- 136 47. O'Connor Á. An overview of the role of diet in the treatment of rheumatoid arthritis.
137 Nutrition Bulletin. 2014;39(1):74-88.
- 138 48. Waterman E, Lockwood B. Active components and clinical applications of olive oil.
139 Altern Med Rev. 2007;12(4):331-42.
- 140 49. S. Silva BS, J. Rocha, R. Direito, A. Fernandes, D. Brites, M. Freitas, E. Fernandes, M.
141 R. Bronze, M. E. Figueira. Protective effects of hydroxytyrosol-supplemented refined olive oil in
142 animal models of acute inflammation and rheumatoid arthritis The Journal of nutritional
143 biochemistry. 2015.
- 144 50. European Commission, Commission Regulation (EC) No 432/2012 of 16 May 2012.
- 145 51. Sanchez-Fidalgo S, Sanchez de Ibarquen L, Cardeno A, Alarcon de la Lastra C. Influence
146 of extra virgin olive oil diet enriched with hydroxytyrosol in a chronic DSS colitis model.
147 European journal of nutrition. 2012;51(4):497-506.
- 148 52. Rosillo MA, Alcaraz MJ, Sanchez-Hidalgo M, Fernandez-Bolanos JG, Alarcon-de-la-
149 Lastra C, Ferrandiz ML. Anti-inflammatory and joint protective effects of extra-virgin olive-oil
150 polyphenol extract in experimental arthritis. The Journal of nutritional biochemistry.
151 2014;25(12):1275-81.
- 152 53. Impellizzeri D, Esposito E, Mazzon E, Paterniti I, Di Paola R, Morittu VM, et al.
153 Oleuropein aglycone, an olive oil compound, ameliorates development of arthritis caused by
154 injection of collagen type II in mice. The Journal of pharmacology and experimental
155 therapeutics. 2011;339(3):859-69.
- 156 54. Martinez-Dominguez E, de la Puerta R, Ruiz-Gutierrez V. Protective effects upon
157 experimental inflammation models of a polyphenol-supplemented virgin olive oil diet.
158 Inflammation research : official journal of the European Histamine Research Society [et al].
159 2001;50(2):102-6.
- 160 55. Bignotto L, Rocha J, Sepodes B, Eduardo-Figueira M, Pinto R, Chaud M, et al. Anti-
161 inflammatory effect of lycopene on carrageenan-induced paw oedema and hepatic ischaemia-
162 reperfusion in the rat. The British journal of nutrition. 2009;102(1):126-33.
- 163 56. Gong D, Geng C, Jiang L, Cao J, Yoshimura H, Zhong L. Effects of hydroxytyrosol-20
164 on carrageenan-induced acute inflammation and hyperalgesia in rats. Phytotherapy research :
165 PTR. 2009;23(5):646-50.
- 166 57. Gimeno E, de la Torre-Carbot K, Lamuela-Raventos RM, Castellote AI, Fito M, de la
167 Torre R, et al. Changes in the phenolic content of low density lipoprotein after olive oil
168 consumption in men. A randomized crossover controlled trial. The British journal of nutrition.
169 2007;98(6):1243-50.
- 170 58. Covas MI, Nyssonen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, et al. The
171 effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Annals of
172 internal medicine. 2006;145(5):333-41.
- 173 59. Covas MI, de la Torre K, Farre-Albaladejo M, Kaikkonen J, Fito M, Lopez-Sabater C, et
174 al. Postprandial LDL phenolic content and LDL oxidation are modulated by olive oil phenolic
175 compounds in humans. Free radical biology & medicine. 2006;40(4):608-16.
- 176 60. Fito M, Cladellas M, de la Torre R, Marti J, Alcantara M, Pujadas-Bastardes M, et al.
177 Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a randomized,
178 crossover, controlled, clinical trial. Atherosclerosis. 2005;181(1):149-58.
- 179 61. Weinbrenner T, Fito M, de la Torre R, Saez GT, Rijken P, Tormos C, et al. Olive oils
180 high in phenolic compounds modulate oxidative/antioxidative status in men. The Journal of
181 nutrition. 2004;134(9):2314-21.

- 182 62. Marrugat J, Covas MI, Fito M, Schroder H, Miro-Casas E, Gimeno E, et al. Effects of
183 differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized
184 controlled trial. *European journal of nutrition*. 2004;43(3):140-7.
- 185 63. Ruiz-Canela M, Martinez-Gonzalez MA. Olive oil in the primary prevention of
186 cardiovascular disease. *Maturitas*. 2011;68(3):245-50.
- 187 64. Katan MB, Zock PL, Mensink RP. Effects of fats and fatty acids on blood lipids in
188 humans: an overview. *The American journal of clinical nutrition*. 1994;60(6 Suppl):1017S-22S.
- 189 65. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the
190 Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The
191 ATTICA Study. *Journal of the American College of Cardiology*. 2004;44(1):152-8.
- 192 66. Huang CL, Sumpio BE. Olive oil, the mediterranean diet, and cardiovascular health.
193 *Journal of the American College of Surgeons*. 2008;207(3):407-16.
- 194 67. Covas MI, Konstantinidou V, Fito M. Olive oil and cardiovascular health. *Journal of*
195 *cardiovascular pharmacology*. 2009;54(6):477-82.
- 196 68. Krauss RM, Dreon DM. Low-density-lipoprotein subclasses and response to a low-fat
197 diet in healthy men. *The American journal of clinical nutrition*. 1995;62(2):478S-87S.
- 198 69. Bos G, Poortvliet MC, Scheffer PG, Dekker JM, Ocke MC, Nijpels G, et al. Dietary
199 polyunsaturated fat intake is associated with low-density lipoprotein size, but not with
200 susceptibility to oxidation in subjects with impaired glucose metabolism and type II diabetes: the
201 Hoorn study. *European journal of clinical nutrition*. 2007;61(2):205-11.
- 202 70. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density
203 lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype,
204 pattern B. *The American journal of medicine*. 1993;94(4):350-6.
- 205 71. Aguilera CM, Mesa MD, Ramirez-Tortosa MC, Nestares MT, Ros E, Gil A. Sunflower
206 oil does not protect against LDL oxidation as virgin olive oil does in patients with peripheral
207 vascular disease. *Clinical nutrition*. 2004;23(4):673-81.
- 208 72. Kratz M, Cullen P, Kannenberg F, Kassner A, Fobker M, Abuja PM, et al. Effects of
209 dietary fatty acids on the composition and oxidizability of low-density lipoprotein. *European*
210 *journal of clinical nutrition*. 2002;56(1):72-81.
- 211 73. FDA. FDA Allows Qualified Health Claim to Decrease Risk of Coronary Heart Disease
212 2004. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108368.htm>.
- 213 74. Fuentes F, Lopez-Miranda J, Perez-Martinez P, Jimenez Y, Marin C, Gomez P, et al.
214 Chronic effects of a high-fat diet enriched with virgin olive oil and a low-fat diet enriched with
215 alpha-linolenic acid on postprandial endothelial function in healthy men. *The British journal of*
216 *nutrition*. 2008;100(1):159-65.
- 217 75. Capurso C, Massaro M, Scoditti E, Vendemiale G, Capurso A. Vascular effects of the
218 Mediterranean diet Part I: Anti-hypertensive and anti-thrombotic effects. *Vascular*
219 *pharmacology*. 2014;63(3):118-26.
- 220 76. Khurana S, Venkataraman K, Hollingsworth A, Piche M, Tai TC. Polyphenols: benefits
221 to the cardiovascular system in health and in aging. *Nutrients*. 2013;5(10):3779-827.
- 222 77. Scientific Opinion on the substantiation of health claims related to polyphenols in olive
223 and protection of LDL particles from oxidative damage (ID 1333, 1638, 1639, 1696, 2865),
224 maintenance of normal blood HDL-cholesterol concentrations (ID 1639), maintenance of normal
225 blood pressure (ID 3781), “anti-inflammatory properties” (ID 1882), “contributes to the upper
226 respiratory tract health” (ID 3468), “can help to maintain a normal function of gastrointestinal

tract” (3779), and “contributes to body defences against external agents” (ID 3467) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA Journal*. 2011;9 (4)(2033).

78. Scientific Opinion on the substantiation of health claims related to olive oil and maintenance of normal blood LDL-cholesterol concentrations (ID 1316, 1332), maintenance of normal (fasting) blood concentrations of triglycerides (ID 1316, 1332), maintenance of normal blood HDL-cholesterol concentrations (ID 1316, 1332) and maintenance of normal blood glucose concentrations (ID 4244) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA Journal*. 2011 9 (4)(2044).

79. Vissers MN, Zock PL, Katan MB. Bioavailability and antioxidant effects of olive oil phenols in humans: a review. *European journal of clinical nutrition*. 2004;58(6):955-65.

80. Rietjens SJ, Bast A, Haenen GR. New insights into controversies on the antioxidant potential of the olive oil antioxidant hydroxytyrosol. *Journal of agricultural and food chemistry*. 2007;55(18):7609-14.

81. Mastralexi A, Nenadis N, Tsimidou MZ. Addressing analytical requirements to support health claims on "olive oil polyphenols" (EC Regulation 432/2012). *Journal of agricultural and food chemistry*. 2014;62(12):2459-61.

82. Romero C, Brenes M. Analysis of total contents of hydroxytyrosol and tyrosol in olive oils. *Journal of agricultural and food chemistry*. 2012;60(36):9017-22.

83. Teres S, Barcelo-Coblijn G, Benet M, Alvarez R, Bressani R, Halver JE, et al. Oleic acid content is responsible for the reduction in blood pressure induced by olive oil. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105(37):13811-6.

84. Yang Q, Alemany R, Casas J, Kitajka K, Lanier SM, Escriba PV. Influence of the membrane lipid structure on signal processing via G protein-coupled receptors. *Molecular pharmacology*. 2005;68(1):210-7.

85. Lahey R, Wang X, Carley AN, Lewandowski ED. Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. *Circulation*. 2014;130(20):1790-9.

86. Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Woodcock SR, Cole MP, et al. Endogenous generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and reperfusion. *Cardiovascular research*. 2010;85(1):155-66.

87. Coles B, Bloodsworth A, Clark SR, Lewis MJ, Cross AR, Freeman BA, et al. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. *Circulation research*. 2002;91(5):375-81.

88. Coles B, Bloodsworth A, Eiserich JP, Coffey MJ, McLoughlin RM, Giddings JC, et al. Nitrolinoleate inhibits platelet activation by attenuating calcium mobilization and inducing phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP. *The Journal of biological chemistry*. 2002;277(8):5832-40.

89. Charles RL, Rudyk O, Pryszyzna O, Kamynina A, Yang J, Morisseau C, et al. Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(22):8167-72.

90. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. *Journal of hypertension*. 2000;18(6):655-73.

91. Sugamura K, Keaney JF, Jr. Reactive oxygen species in cardiovascular disease. *Free radical biology & medicine*. 2011;51(5):978-92.

- 273 92. Raedschelders K, Ansley DM, Chen DD. The cellular and molecular origin of reactive
274 oxygen species generation during myocardial ischemia and reperfusion. *Pharmacology &*
275 *therapeutics*. 2012;133(2):230-55.
- 276 93. Ross R. Atherosclerosis--an inflammatory disease. *The New England journal of*
277 *medicine*. 1999;340(2):115-26.
- 278 94. Dell'Agli M, Fagnani R, Galli GV, Maschi O, Gilardi F, Bellosta S, et al. Olive oil
279 phenols modulate the expression of metalloproteinase 9 in THP-1 cells by acting on nuclear
280 factor-kappaB signaling. *Journal of agricultural and food chemistry*. 2010;58(4):2246-52.
- 281 95. Dell'Agli M, Fagnani R, Mitro N, Scurati S, Masciadri M, Mussoni L, et al. Minor
282 components of olive oil modulate proatherogenic adhesion molecules involved in endothelial
283 activation. *Journal of agricultural and food chemistry*. 2006;54(9):3259-64.
- 284 96. Gonzalez-Correa JA, Navas MD, Munoz-Marin J, Trujillo M, Fernandez-Bolanos J, de la
285 Cruz JP. Effects of hydroxytyrosol and hydroxytyrosol acetate administration to rats on platelet
286 function compared to acetylsalicylic acid. *Journal of agricultural and food chemistry*.
287 2008;56(17):7872-6.
- 288 97. Dollery CM, Libby P. Atherosclerosis and proteinase activation. *Cardiovascular research*.
289 2006;69(3):625-35.
- 290 98. Barderas MG, Vivanco F, Alvarez-Llamas G. Vascular proteomics. *Methods in molecular*
291 *biology*. 2013;1000:1-20.
- 292 99. von Zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, et al.
293 Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery
294 atherosclerosis in symptomatic patients. *Journal of proteome research*. 2009;8(1):335-45.
- 295 100. Zimmerli LU, Schiffer E, Zurbig P, Good DM, Kellmann M, Moulds L, et al. Urinary
296 proteomic biomarkers in coronary artery disease. *Molecular & cellular proteomics : MCP*.
297 2008;7(2):290-8.
- 298 101. Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P, et al. Serum
299 matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease.
300 *Scandinavian journal of clinical and laboratory investigation*. 2002;62(5):337-42.
- 301 102. Scoditti E, Nestola A, Massaro M, Calabriso N, Storelli C, De Caterina R, et al.
302 Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human
303 monocytes via PKCalpha and PKCbeta1 inhibition. *Atherosclerosis*. 2014;232(1):17-24.
- 304 103. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, Martines G, et al.
305 Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2
306 inhibition in human vascular endothelial cells: a potentially protective mechanism in
307 atherosclerotic vascular disease and cancer. *Archives of biochemistry and biophysics*.
308 2012;527(2):81-9.
- 309 104. Delles C, Schiffer E, von Zur Muhlen C, Peter K, Rossing P, Parving HH, et al. Urinary
310 proteomic diagnosis of coronary artery disease: identification and clinical validation in 623
311 individuals. *Journal of hypertension*. 2010;28(11):2316-22.
- 312 105. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix
313 metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism.
314 *Journal of cellular physiology*. 2002;192(2):160-70.
- 315 106. Lafleur MA, Hollenberg MD, Atkinson SJ, Knauper V, Murphy G, Edwards DR.
316 Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-
317 MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active
318 species. *The Biochemical journal*. 2001;357(Pt 1):107-15.

319 107. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species
320 produced by macrophage-derived foam cells regulate the activity of vascular matrix
321 metalloproteinases in vitro. Implications for atherosclerotic plaque stability. *The Journal of*
322 *clinical investigation*. 1996;98(11):2572-9.

323 108. Oak MH, El Bedoui J, Anglard P, Schini-Kerth VB. Red wine polyphenolic compounds
324 strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to
325 thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth
326 muscle cells. *Circulation*. 2004;110(13):1861-7.

327 109. El Bedoui J, Oak MH, Anglard P, Schini-Kerth VB. Catechins prevent vascular smooth
328 muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression. *Cardiovascular*
329 *research*. 2005;67(2):317-25.

330 110. Silva S, Bronze MR, Figueira ME, Siwy J, Mischak H, Combet E, et al. Impact of a 6-wk
331 olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery
332 disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled,
333 double-blind study. *The American journal of clinical nutrition*. 2015;101(1):44-54.

334 111. Wang M, Lamers RJ, Korthout HA, van Nesselrooij JH, Witkamp RF, van der Heijden R,
335 et al. Metabolomics in the context of systems biology: bridging traditional Chinese medicine and
336 molecular pharmacology. *Phytotherapy research : PTR*. 2005;19(3):173-82.

337 112. Finley Austin MJ, Babiss L. Commentary: where and how could biomarkers be used in
338 2016? *The AAPS journal*. 2006;8(1):E185-9.

339 113. Schanstra JP, Mischak H. Proteomic urinary biomarker approach in renal disease: from
340 discovery to implementation. *Pediatric nephrology*. 2014.

341 114. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, et al.
342 Recommendations for biomarker identification and qualification in clinical proteomics. *Science*
343 *translational medicine*. 2010;2(46):46ps2.

344 115. Stegemann C, Didangelos A, Barallobre-Barreiro J, Langley SR, Mandal K, Jahangiri M,
345 et al. Proteomic identification of matrix metalloproteinase substrates in the human vasculature.
346 *Circ-Cardiovasc Gene*. 2013;6(Article):106-17.

347 116. Mischak H, Rossing P. Proteomic biomarkers in diabetic nephropathy--reality or future
348 promise? *Nephrology, dialysis, transplantation : official publication of the European Dialysis and*
349 *Transplant Association - European Renal Association*. 2010;25(9):2843-5.

350 117. Lescuyer P, Hochstrasser D, Rabilloud T. How shall we use the proteomics toolbox for
351 biomarker discovery? *J Proteome Res*. 2007;6(9):3371-6.

352 118. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method
353 for proteome analysis. *Nat Methods*. 2009;6(5):359-62.

354 119. Husi H, Van Agtmael T, Mullen W, Bahlmann FH, Schanstra JP, Vlahou A, et al.
355 Proteome-Based Systems Biology Analysis of the Diabetic Mouse Aorta Reveals Major Changes
356 in Fatty Acid Biosynthesis as Potential Hallmark in Diabetes Mellitus-Associated Vascular
357 Disease. *Circ-Cardiovasc Gene*. 2014;7(2):161-70.

358 120. Thongboonkerd V, McLeish KR, Arthur JM, Klein JB. Proteomic analysis of normal
359 human urinary proteins isolated by acetone precipitation or ultracentrifugation. *Kidney*
360 *international*. 2002;62(4):1461-9.

361 121. Thongboonkerd V, Malasit P. Renal and urinary proteomics: current applications and
362 challenges. *Proteomics*. 2005;5(4):1033-42.

363 122. Mischak H, Kolch W, Aivaliotis M, Bouyssie D, Court M, Dihazi H, et al.
364 Comprehensive human urine standards for comparability and standardization in clinical
365 proteome analysis. *Proteomics Clinical applications*. 2010;4(4):464-78.

366 123. Albalat A, Franke J, Gonzalez J, Mischak H, Zurbig P. Urinary proteomics based on
367 capillary electrophoresis coupled to mass spectrometry in kidney disease. *Methods in molecular*
368 *biology*. 2013;919:203-13.

369 124. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, Coon JJ, et al. Naturally
370 occurring human urinary peptides for use in diagnosis of chronic kidney disease. *Molecular &*
371 *cellular proteomics : MCP*. 2010;9(11):2424-37.

372 125. Metzger J, Kirsch T, Schiffer E, Ulger P, Menten E, Brand K, et al. Urinary excretion of
373 twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. *Kidney*
374 *international*. 2010;78(12):1252-62.

375 126. Dawson J, Walters M, Delles C, Mischak H, Mullen W. Urinary proteomics to support
376 diagnosis of stroke. *PloS one*. 2012;7(5):e35879.

377 127. Mischak H, Schanstra JP. CE-MS in biomarker discovery, validation, and clinical
378 application. *Proteomics Clinical applications*. 2011;5(1-2):9-23.

379 128. Coon JJ, Zurbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, et al. CE-MS
380 analysis of the human urinary proteome for biomarker discovery and disease diagnostics.
381 *Proteomics Clinical applications*. 2008;2(7-8):964.

382 129. Lee RT, Libby P. The unstable atheroma. *Arteriosclerosis, thrombosis, and vascular*
383 *biology*. 1997;17(10):1859-67.

384 130. Zurbig P, Jerums G, Hovind P, Macisaac RJ, Mischak H, Nielsen SE, et al. Urinary
385 proteomics for early diagnosis in diabetic nephropathy. *Diabetes*. 2012;61(12):3304-13.

386 131. de Roos B, Zhang X, Rodriguez Gutierrez G, Wood S, Rucklidge GJ, Reid MD, et al.
387 Anti-platelet effects of olive oil extract: in vitro functional and proteomic studies. *European*
388 *journal of nutrition*. 2011;50(7):553-62.

389 132. Arbones-Mainar JM, Ross K, Rucklidge GJ, Reid M, Duncan G, Arthur JR, et al. Extra
390 virgin olive oils increase hepatic fat accumulation and hepatic antioxidant protein levels in
391 APOE^{-/-} mice. *Journal of proteome research*. 2007;6(10):4041-54.

392 133. Ge Y, Wang TJ. Identifying novel biomarkers for cardiovascular disease risk prediction.
393 *Journal of internal medicine*. 2012;272(5):430-9.

394 134. Sharma P, Cosme J, Gramolini AO. Recent advances in cardiovascular proteomics. *J*
395 *Proteomics*. 2013;81:3-14.

396 135. Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA, et al.
397 Advances in urinary proteome analysis and biomarker discovery. *Journal of the American*
398 *Society of Nephrology*. 2007;18(4):1057-71.

399 136. Julian BA, Suzuki H, Suzuki Y, Tomino Y, Spasovski G, Novak J. Sources of urinary
400 proteins and their analysis by urinary proteomics for the detection of biomarkers of disease.
401 *Proteom Clin Appl*. 2009;3(9):1029-43.

402 137. Perona JS, Cabello-Moruno R, Ruiz-Gutierrez V. The role of virgin olive oil components
403 in the modulation of endothelial function. *The Journal of nutritional biochemistry*.
404 2006;17(7):429-45.

405 138. Guillen N, Acin S, Navarro MA, Perona JS, Arbones-Mainar JM, Arnal C, et al. Squalene
406 in a sex-dependent manner modulates atherosclerotic lesion which correlates with hepatic fat
407 content in apoE-knockout male mice. *Atherosclerosis*. 2008;197(1):72-83.

408 139. Monte E, Vondriska TM. Epigenomes: the missing heritability in human cardiovascular
409 disease? *Proteomics Clinical applications*. 2014;8(7-8):480-7.

410 140. Konstantinidou V, Covas MI, Munoz-Aguayo D, Khymenets O, de la Torre R, Saez G, et
411 al. In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the
412 Mediterranean diet: a randomized controlled trial. *FASEB journal : official publication of the*
413 *Federation of American Societies for Experimental Biology*. 2010;24(7):2546-57.

414 141. Camargo A, Ruano J, Fernandez JM, Parnell LD, Jimenez A, Santos-Gonzalez M, et al.
415 Gene expression changes in mononuclear cells in patients with metabolic syndrome after acute
416 intake of phenol-rich virgin olive oil. *BMC genomics*. 2010;11:253.

417 142. Vazquez-Fresno R, Llorach R, Urpi-Sarda M, Lupianez-Barbero A, Estruch R, Corella D,
418 et al. Metabolomic Pattern Analysis after Mediterranean Diet Intervention in a Nondiabetic
419 Population: A 1- and 3-Year Follow-up in the PREDIMED Study. *Journal of proteome research*.
420 2015;14(1):531-40.

421 143. Noratto GD, Angel-Morales G, Talcott ST, Mertens-Talcott SU. Polyphenolics from acai
422 (*Euterpe oleracea* Mart.) and red muscadine grape (*Vitis rotundifolia*) protect human umbilical
423 vascular Endothelial cells (HUVEC) from glucose- and lipopolysaccharide (LPS)-induced
424 inflammation and target microRNA-126. *Journal of agricultural and food chemistry*.
425 2011;59(14):7999-8012.

426 144. Milenkovic D, Jude B, Morand C. miRNA as molecular target of polyphenols underlying
427 their biological effects. *Free radical biology & medicine*. 2013;64:40-51.

428 145. Garcia-Gonzalez DL, Aparicio R. Research in olive oil: challenges for the near future.
429 *Journal of agricultural and food chemistry*. 2010;58(24):12569-77.

430 146. Martin-Pelaez S, Covas MI, Fito M, Kusar A, Pravst I. Health effects of olive oil
431 polyphenols: recent advances and possibilities for the use of health claims. *Molecular nutrition &*
432 *food research*. 2013;57(5):760-71.

433 147. Dunn MJ. *Proteomics clinical applications reviews 2013*. *Proteomics Clinical*
434 *applications*. 2013;7(1-2):4-7.

435 148. Levi B, Werman MJ. Long-term fructose consumption accelerates glycation and several
436 age-related variables in male rats. *J Nutr*. 1998;128(9):1442-9.

437 149. Kontogianni VG, Charisiadis P, Margianni E, Lamari FN, Gerothanassis IP, Tzakos AG.
438 Olive leaf extracts are a natural source of advanced glycation end product inhibitors. *Journal of*
439 *medicinal food*. 2013;16(9):817-22.

440 150. Vlassopoulos A, Lean ME, Combet E. Protein-phenolic interactions and inhibition of
441 glycation - combining a systematic review and experimental models for enhanced physiological
442 relevance. *Food & function*. 2014;5(10):2646-55.

443

Figure 1 – Chronic inflammation model and impact on rats paw edema (ANOVA, * $p < 0.001$ vs. positive control – Rheumatoid Arthritis, + $p < 0.01$ vs. Refined Olive Oil; OHTYR = hydroxytyrosol) (adapted from Silva *et al.*⁽⁴⁹⁾)

